Quick Takeaways
- Avoro Capital Advisors LLC filed SCHEDULE 13G for Definium Therapeutics, Inc. Common Shares, no par value per share.
- Disclosed ownership: 5.1%.
- Date of event: 31 Dec 2025.
Avoro Capital Advisors LLC - 31 Dec 2025 SCHEDULE 13G Report for Definium Therapeutics, Inc. Common Shares, no par value per share
- Filing Manager
- Avoro Capital Advisors LLC
- Reporting Manager
- Avoro Capital Advisors LLC
- Shares outstanding
- 98,425,197 shares
- Disclosed Ownership
- 5,000,000 shares
- Ownership
- 5.1%
- Form type
- SCHEDULE 13G
- Filing time
- 17 Feb 2026, 09:00:20 UTC
- Date of event
- 31 Dec 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"Avoro Capital Advisors LLC disclosed 5.1% ownership in Definium Therapeutics, Inc. Common Shares, no par value per share on 31 Dec 2025."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 17 Feb 2026, 09:00.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Official SEC Source
Backed by Schedule 13D/13G
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
See Original FilingReporting Managers (2)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Avoro Capital Advisors LLC | 5.1% | 5,000,000 | 5,000,000 | 0 | /s/ Scott Epstein | Scott Epstein, Chief Operating Officer and Chief Compliance Officer | |
| Behzad Aghazadeh | 5.1% | 5,000,000 | 5,000,000 | 0 | /s/ Behzad Aghazadeh | Behzad Aghazadeh, Individually |